-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Amylyx Pharmaceuticals, Raises Price Target to $52

Benzinga·08/19/2026 11:04:20
语音播报
Baird analyst Joel Beatty maintains Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Outperform and raises the price target from $28 to $52.